The Dawning of Translational Breast Cancer: From Bench to Bedside
- 28 December 2017
- book chapter
- Published by Springer Nature
- Vol. 1026, 1-25
Abstract
Breast cancer is one of the world’s leading causes of death in women. Although tumor initiation and progression are predominantly driven by somatic or acquired (epi) genetic alterations that govern signaling abnormalities, growing evidence suggests that the inflammatory microenvironments of cancer also play a role. Molecular characterization of breast cancer biology is essential for high-efficient management of this disease in clinical practice. Translating basic research into clinically valuable biomarkers for diagnosis, prognosis, and prediction of response to treatment and into precisely targeted therapies is crucial for the development of precision medicine in breast cancer. Such a process is known as “from bench to bedside.” In this chapter, we will present an overview of breast cancer pathogenesis and selected translational advances in multistage clinical settings and aim to illustrate the dawning of precision medicine implementation in managing human breast malignancies.Keywords
This publication has 208 references indexed in Scilit:
- How integrins control breast biologyCurrent Opinion in Cell Biology, 2013
- Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefitBreast Cancer Research and Treatment, 2012
- Clinical trial results of the HER‐2/neu (E75) vaccine to prevent breast cancer recurrence in high‐risk patientsCancer, 2011
- Tumor Metastasis: Molecular Insights and Evolving ParadigmsCell, 2011
- CCL18 from Tumor-Associated Macrophages Promotes Breast Cancer Metastasis via PITPNM3Cancer Cell, 2011
- Deconstructing the molecular portraits of breast cancerMolecular Oncology, 2010
- CD4+ T Cells Regulate Pulmonary Metastasis of Mammary Carcinomas by Enhancing Protumor Properties of MacrophagesCancer Cell, 2009
- HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitorsCancer Treatment Reviews, 2009
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell, 2004
- Integrins: Versatility, modulation, and signaling in cell adhesionCell, 1992